Abeona Therapeutics receives Orphan Drug designation in EU for ABO-202 gene therapy
Abeona Therapeutics announced the EMA Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona’s gene therapy program ABO-202 for treatment of subjects with neuronal ceroid lipofuscinosis, also known as Batten Disease, a fatal lysosomal storage disease. April 20, 2018